Corporate | 26 March 2015 07:30
DGAP-News: Evotec AG / Key word(s): Alliance
2015-03-26 / 07:30
---------------------------------------------------------------------
Hamburg, Germany - 26 March 2015: Evotec AG (Frankfurt Stock Exchange: EVT,
TecDAX, ISIN: DE0005664809) today announced it has entered into a
multi-target screening collaboration on several ion channel targets, with
Asahi Kasei Pharma Corporation, a wholly owned subsidiary of Asahi Kasei
Corporation, Tokyo, Japan.
Under the terms of the agreement, Evotec will use its world-class ion
channel platform to identify inhibitors of multiple ion channel targets.
Dr Mario Polywka, Chief Operating Officer of Evotec, stated: "We are
extremely pleased that Asahi Kasei Pharma has decided to undertake these
projects with Evotec. Our expertise and platform on ion channel drug
discovery has proven to add significant value to our partner's programmes
and we look forward to supporting Asahi Kasei Pharma in their own ion
channel drug discovery efforts."
Financial terms were not disclosed.
ABOUT ASAHI KASEI
The Asahi Kasei Group is a diversified group of companies led by holding
company Asahi Kasei Corp., with operations in the chemicals and fibers,
homes and construction materials, electronics, and health care business
sectors. Its health care operations include devices and systems for acute
critical care, dialysis, therapeutic apheresis, transfusion, and
manufacture of biotherapeutics, as well as pharmaceuticals, diagnostic
reagents, and nutritional products. With more than 29,000 employees around
the world, the Asahi Kasei Group serves customers in more than 100
countries. For more information, visit www.asahi-kasei.co.jp/asahi/en/.
ABOUT EVOTEC AG
Evotec is a drug discovery alliance and development partnership company
focused on rapidly progressing innovative product approaches with leading
pharmaceutical and biotechnology companies, academics, patient advocacy
groups and venture capitalists. We operate worldwide providing the highest
quality stand-alone and integrated drug discovery solutions, covering all
activities from target-to-clinic. The Company has established a unique
position by assembling top-class scientific experts and integrating
state-of-the-art technologies as well as substantial experience and
expertise in key therapeutic areas including neuroscience, pain, metabolic
diseases as well as oncology, inflammation and infectious diseases. Evotec
has long-term discovery alliances with partners including Bayer, Boehringer
Ingelheim, CHDI, Genentech, Janssen Pharmaceuticals, MedImmune/AstraZeneca,
Roche and UCB. In addition, the Company has existing development
partnerships and product candidates both in clinical and pre-clinical
development. These include partnerships with Boehringer Ingelheim and
MedImmune in the field of diabetes, with Janssen Pharmaceuticals in the
field of depression and with Roche in the field of Alzheimer's disease. For
additional information please go to www.evotec.com.
FORWARD LOOKING STATEMENTS - Information set forth in this press release
contains forward-looking statements, which involve a number of risks and
uncertainties. The forward-looking statements contained herein represent
the judgement of Evotec as of the date of this report. Such forward-looking
statements are neither promises nor guarantees, but are subject to a
variety of risks and uncertainties, many of which are beyond our control,
and which could cause actual results to differ materially from those
contemplated in these forward-looking statements. We expressly disclaim any
obligation or undertaking to release publicly any updates or revisions to
any such statements to reflect any change in our expectations or any change
in events, conditions or circumstances on which any such statement is
based.
Contact Evotec AG:
Gabriele Hansen, VP Corporate Communications & Investor Relations, Phone:
+49.(0)40.56081-255, gabriele.hansen@evotec.com
---------------------------------------------------------------------
2015-03-26 Dissemination of a Corporate News, transmitted by DGAP - a
service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.
The DGAP Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Media archive at www.dgap-medientreff.de and www.dgap.de
---------------------------------------------------------------------
Language: English
Company: Evotec AG
Manfred Eigen Campus / Essener Bogen 7
22419 Hamburg
Germany
Phone: +49 (0)40 560 81-0
Fax: +49 (0)40 560 81-222
E-mail: info@evotec.com
Internet: www.evotec.com
ISIN: DE0005664809
WKN: 566480
Indices: TecDAX
Listed: Regulated Market in Frankfurt (Prime Standard); Regulated
Unofficial Market in Berlin, Dusseldorf, Hamburg, Hanover,
Munich, Stuttgart
End of News DGAP News-Service
---------------------------------------------------------------------
337659 2015-03-26